Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUNCH CD study of RBX2660 for recurrent CDAD
NCT01925417Phase 2Completed
- Sponsor
- Rebiotix Inc.
- Start
- Aug 2013
- Primary completion
- Mar 2014
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of RBX2660 in Clostridium difficile infection (CDI), sponsored by Rebiotix Inc.. Started Aug 2013; status: completed.
02
Drugs
RBX2660
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01925417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01925417.